Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rallybio Corp.

0.5818
-0.0442-7.06%
Post-market: 0.59920.0174+2.99%16:42 EDT
Volume:277.26K
Turnover:165.55K
Market Cap:24.31M
PE:-0.62
High:0.6300
Open:0.6300
Low:0.5800
Close:0.6260
52wk High:1.25
52wk Low:0.2201
Shares:41.79M
Float Shares:19.86M
Volume Ratio:0.72
T/O Rate:1.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9313
EPS(LYR):-1.3268
ROE:-66.12%
ROA:-36.34%
PB:0.53
PE(LYR):-0.44

Loading ...

BRIEF-Rallybio Q1 Net Income USD -9.439 Million

Reuters
·
May 08

Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

Business Wire
·
Apr 29

U.S. RESEARCH ROUNDUP- CNB Financial, Disney, Triumph Group

Reuters
·
Apr 15

Rallybio downgraded to Hold from Buy at JonesResearch

TIPRANKS
·
Apr 15

Evercore ISI Downgrades Rallybio to In Line From Outperform

MT Newswires Live
·
Apr 14

Rallybio downgraded to In Line from Outperform at Evercore ISI

TIPRANKS
·
Apr 12

HC Wainwright Downgrades Rallybio to Neutral From Buy

MT Newswires Live
·
Apr 09

Citizens JMP downgrades Rallybio on RLYB212 discontinuation

TIPRANKS
·
Apr 09

JMP Securities downgrades Rallybio (RLYB) to a Hold

TIPRANKS
·
Apr 08

BRIEF-Rallybio Corp Discontinues Rlyb212 Program For Prevention Of Fnait

Reuters
·
Apr 08

Rallybio Terminates RLYB212 Development for Rare Immune Disorder; Shares Fall

MT Newswires Live
·
Apr 08

Rallybio Discontinues Development of Treatment for Prevention of Rare Immune Disorder

Dow Jones
·
Apr 08

Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

Business Wire
·
Apr 08

Rallybio Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 17

Rallybio’s Promising Financial Stability and Strategic Clinical Advancements Drive Buy Rating

TIPRANKS
·
Mar 14

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 14

Rallybio Corporation Reports 2024 Financial Results and Progress

TIPRANKS
·
Mar 14

Promising Developments and Financial Stability Support Buy Rating for Rallybio

TIPRANKS
·
Mar 14

Rallybio Q4 EPS $(0.25) Beats $(0.29) Estimate, Sales $38.00K Miss $75.00K Estimate

Benzinga
·
Mar 13

BRIEF-Rallybio Q4 Net Income USD -11.044 Million

Reuters
·
Mar 13